In Brief: J&J v. Millenson
This article was originally published in The Gray Sheet
J&J v. Millenson: Arbitrator determines Johnson & Johnson's premarket submission in France violated a milestone payment agreement in former Direct Access Diagnostic President and CEO Elliot Millenson's contract. As a result of the decision, J&J agrees to pay Millenson $500,000 for his role in developing the Confide home HIV test system. Millenson and J&J also are involved in ongoing litigation in New Jersey Superior Court over ownership of DAD ("The Gray Sheet" Aug. 5, p. 10). A court date to determine whether J&J will have to relinquish all DAD assets to Millenson has been set for Oct. 16...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.